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Abstract
Background: The development of the face occurs during the early days of in-
trauterine life by the formation of facial processes from the first Pharyngeal arch. 
Derangement in these well-organized fusion events results in Orofacial clefts (OFC). 
Van der Woude syndrome (VWS) is one of the most common causes of syndromic 
cleft lip and/or palate accounting for 2% of all cases. Mutations in the IRF6 gene 
account for 70% of cases with the majority of these mutations located in the DNA-
binding (exon 3, 4) or protein-binding domains (exon 7–9). The current study was 
designed to update the list of IRF6 variants reported for VWS by compiling all the 
published mutations from 2013 to date as well as including the previously unreported 
VWS cases from Africa and Puerto Rico.
Methods: We used PubMed with the search terms; "Van der Woude syndrome," 
“Popliteal pterygium syndrome,” "IRF6," and "Orofacial cleft" to identify eligible 
studies. We compiled the CADD score for all the mutations to determine the percent-
age of deleterious variants.
Results: Twenty-one new mutations were identified from nine papers. The major-
ity of these mutations were in exon 4. Mutations in exon 3 and 4 had CADD scores 
between 20 and 30 and mutations in exon 7–9 had CADD scores between 30 and 
40. The presence of higher CADD scores in the protein-binding domain (exon 7–9) 
further confirms the crucial role played by this domain in the function of IRF6. In 
the new cases, we identified five IRF6 mutations, three novel missense mutations 
(p.Phe36Tyr, p.Lys109Thr, and p.Gln438Leu), and two previously reported non-
sense mutations (p.Ser424*and p.Arg250*).
Conclusion: Mutations in the protein and DNA-binding domains of IRF6 ranked 
among the top 0.1% and 1% most deleterious genetic mutations, respectively. Overall, 
these findings expand the range of VWS mutations and are important for diagnostic 
and counseling purposes.
K E Y W O R D S
Combined Annotation Dependent Depletion score, interferon regulatory factor 6, orofacial cleft, 
Popliteal pterygium syndrome, Van der Woude syndrome
1 |  INTRODUCTION
Facial development occurs during the early days of intrauter-
ine life by the formation of facial processes from the first pha-
ryngeal arch and their subsequent fusion (Afshar, Brugmann, 
& Helms, 2012). Derangement in this process results in oro-
facial clefts. Orofacial clefts are a group of congenital defects 
that are present with the discontinuity of the affected part of 
the face, which can either occur in isolation (non-syndromic), 
or together with other defects (syndromic), with a preponder-
ance of the former (Gatta et al., 2004). Van der Woude syn-
drome (VWS) (OMIM: 119300 and 606713), an autosomal 
dominant disorder with variable expression and a high level 
of penetrance (Lam, David, Townsend, & Anderson, 2010), 
is the most common syndromic cleft accounting for 2% of 
all cases (Murray et al., 1997) It classically presents with lip 
pits and either cleft lip, cleft lip/palate, or cleft palate only. 
(Kondo et al., 2002; Malik, Wilcox, & Naz, 2013; Van Der 
Woude, 1954).
Mutations in the Interferon Regulatory Factor Six 
(IRF6) (OMIM: 607199) (Kondo et al., 2002; Ural, Bilgen, 
Çakmakli, & Bekerecioğlu, 2019), and Grainy Head Like 
Three (GRHL3) (OMIM: 608317) (Peyrard-Janvid et al., 
2014) genes have been shown to cause VWS and Popliteal 
pterygium syndrome (PPS) (OMIM: 119500). IRF6 is the 
only member of the IRF gene family involved in the craniofa-
cial development (Starink et al., 2017). It is a protein-coding 
gene with a highly conserved N terminal DNA-binding do-
main and a less conserved C terminal protein-binding domain 
(Ben, Jabs, & Chong, 2005; Kondo et al., 2002). Non- random 
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mutations in the coding regions of IRF6 account for 70% of 
cases of VWS with the majority of these mutations located at 
the DNA-binding domain (exon 3, 4) and the protein-binding 
domain (exon 7–9) (Ferreira de Lima et al., 2009).
There are several bioinformatics tools used to predict the 
pathogenicity of genetic mutations (Adzhubei et  al.,  2010; 
Kumar, Henikoff, & Ng, 2009; Venselaar, Te Beek, Kuipers, 
Hekkelman, & Vriend, 2010) including SIFT, Polyphen and 
HOPE. However, the conflicting results from existing bioin-
formatics tools (Hicks, Wheeler, Plon, & Kimmel, 2011), the 
paucity of the functional data on reported variants, as well 
as the need for a more robust tool to accurately predict the 
clinical implications of these variants led to the development 
of the Combined Annotation Dependent Depletion score 
(CADD score, Kircher et al. 2014).
CADD is a comprehensive prediction tool developed 
by Kircher, Jain, O’Roak, Cooper, and Shendure (2014). It 
merges the algorithms of over 60 other previously developed 
tools to produce a single result. It thus compensates for the 
loopholes of the other individual tools and allowing for a 
more accurate prediction of the pathogenicity of these muta-
tions. This is achieved via a scoring system linked to existing 
genomic databases using a score of 20 for the top 1% and 30 
for the top 0.1% of the most deleterious genetic mutations in 
the human genome (Kircher et al., 2014).
The current study reviewed the literature to update the 
list of IRF6 variants reported for VWS, predicted their clin-
ical significance using the CADD score, and reported novel 
IRF6 variants identified in Africans and Puerto Ricans with 
VWS.
2 |  METHODOLOGY
2.1 | Literature search
We used PubMed with the search terms: "Van der Woude 
syndrome and Popliteal pterygium syndrome," "IRF6," 
and "Orofacial cleft" to identify studies that reported novel 
mutation(s) not found in the Leslie et al.  (2013) study. We 
also compiled the CADD score for all the reported mutations 
using the CADD single nucleotide variant (SNV) look-up 
feature (GRCh37-v1.4 version).
2.2 | New study population and sample 
information
2.2.1 | Ethical compliance
The new study populations include Nigerians, Ghanaians, 
Ethiopians, and Puerto-Ricans. Ethical approval for this 
project was received from the Institutional Review Boards 
(IRBs) at the University of Iowa (Iowa approvals num-
bers: 201101720), Lagos University Teaching Hospital Idi-
Araba, Lagos (IRB approval number: ADM/DCST/HREC/
VOL.XV/321), Obafemi Awolowo University Teaching 
Hospital Ile-Ife (IRB approval number: ERC/2011/12/01), 
Kwame Nkrumah University of Science and Technology 
(IRB approval number: CHRPE/RC/018/13), the Addis 
Ababa University (IRB approval number: 003/10/surg), the 
University of Puerto-Rico (IRB approval number: 0640111), 
and Kwazulu-Natal University (IRB approval number: 
BE309/18).
2.3 | DNA sequencing
Primer sequences that were used to amplify exons 1 to 9 of 
IRF6 (RefSeq NM_006147.4) have been previously pub-
lished (Ferreira Butali et al., 2014; de Lima et al., 2009) and 
available on request. All DNA processing protocols, PCR 
conditions, and electrophoretic procedures are available 
at the Murray laboratory website (http://genet ics.uiowa.
edu/proto cols.php). The amplified DNA products were 
sent to Functional Biosciences in Madison, Wisconsin for 
sequencing using an ABI 3730XL DNA Sequencer. The 
sequence data and variants were viewed with CONSED. 
Each variant and genomic location that was revealed by 
CONSED were confirmed using the “Blat” function of 
THE UCSC Genome Browser. The functional conse-
quences of variants were predicted using CADD, SIFT, 
and Polyphen-2 to determine pathogenic and benign vari-
ants. HOPE was used to create a simulation of the mutant 
protein structure. The effect of a variant on mRNA splicing 
was ascertained using Human Splicing Finder 3.0 (http://
www.umd.be/HSF3/). Furthermore, the effect of a variant 
on a regulatory region was predicted, using RegulomeDB 
(http://regul omedb.org/).
The Minor Allele Frequencies or the novelty of a vari-
ant was ascertained by comparing it to variants in the 1000 
Genomes (http://brows er.1000g enomes.org/index.html), 
Exome Variant Server (http://evs.gs.washi ngton.edu/EVS/), 
dbSNP (www.ncbi.nlm.nih.gov/SNP/) ExAC Browser 
(http://exac.broad insti tute.org/) and gnomAD (https://gno-
mad.broad insti tute.org/). If a variant has never been reported 
before in the literature or these databases, it was categorized 
as “novel.” When a variant of interest was found in a proband, 
the samples from their parents were sequenced. Identified 
variants were confirmed by sequencing in the reverse direc-
tion. The presence or absence of the mutation in the parent's 
DNA was used to determine if such variation was “de novo” 
or segregated in the family.
The data that support the findings of this study are openly 
available in [repository name e.g., “figshare”] at http://doi.
org/[doi], reference number [reference number].
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3 |  RESULTS
Following our literature search for variants reported after 
the Leslie et  al.  (2013) study, we identified 21 new muta-
tions from nine papers and compiled a CADD score for them 
(Table  1, Table  S1). The majority (69) of these mutations 
were in exon 4 with 194 mutations having CADD scores in 
the 20s and 30s (Table 1, Figure 1). There were 13 nonsense 
mutations with scores of 40+. A nonsense mutation in exon 
8 was discovered in a patient with PPS and was predicted 
to be a dominant-negative mutation with a CADD score of 
54 (Table 1). These high CADD scores rank IRF6 mutations 
among the top 0.1 to 0.0001% most deleterious mutations in 
the human genome.
In the current study, we identified five mutations, three 
novel missense mutations: p.Phe36Tyr, p.Lys109Thr, p.Gl-
n438Leu, and two previously reported nonsense mutations: 
p.Ser424*and p.Arg250*. The three missense mutations were 
predicted to be probably damaging/ damaging by Polyphen-2 
and Sift prediction tools. The p.Phe36Tyr mutation located 
in exon 3 was identified in family A where both mother and 
child had shallow lip pits characteristic of VWS with an un-
affected father (Figure 2). The p.Lys109Thr mutation located 
in exon 4 was identified in family B where samples for both 
parents were not available but were absent in the maternal 
grandmother. Thus, we were unable to determine the mode of 
inheritance. The proband with p.Gln438Leu mutation in exon 
9, identified in family C, had incomplete cleft lip without lip 
pits and both parents appear clinically unaffected. The known 
nonsense mutations were in exon 9 and 7, respectively. The 
missense mutations (p.Phe36Tyr, p.Lys109Thr and p.Gl-
n438Leu) had CADD scores 29, 23.6, and 25.5, while the 
nonsense mutations (p. Ser424* and p. Arg250*) had CADD 
scores of 40 and 43, respectively, as shown in (Table  2). 
The data that support the findings of this study are openly 
available in ClinVar at https://submit.ncbi.nlm.nih.gov/clinv 
ar/, submission ID [SUB7353596].
4 |  DISCUSSION
Non-random mutations in the IRF6 highly conserved DNA-
binding domain (exon 3 and 4) and the less conserved pro-
tein-binding domain (exon 7–9) have been implicated in the 
etiology of VWS and PPS (Ferreira de Lima et  al.,  2009). 
In this study, we found five IRF6 mutations after sequenc-
ing VWS families from Africa and Puerto Rico. These in-
clude p.Phe36Tyr, p.Lys109Thr, p.Ser424*, p.Arg250*, 
and p.Gln438Leu. The missense mutation (p.Phe36Tyr), 
F I G U R E  1  Box plot showing higher 
Combined Annotation Dependent Depletion 
score in the protein binding domain (exon 
3 and 4) compared to the DNA binding 
domain (exon 7–9) of IRF6
F I G U R E  2  Showing the structural changes for the amino acid 
change p. Phe36Tyr (a), p. Pro109thr (b) and p. Glu438Leu (c)
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identified in a Puerto Rican family segregates in the family 
(proband and mother) and confirms a maternal mode of in-
heritance. Based on the HOPE analyses, we observed that 
the mutant is in a domain that is important for the binding of 
other protein molecules. The mutant is large and will not fit 
into the core of the IRF6 protein where the wild type resides. 
Also, the wild-type residue is more hydrophobic and thus the 
mutant might disturb the interaction between domains and 
thereby affect the function of the protein. The p.Lys109thr 
mutant is smaller compared to the wild type leading to an 
empty space in the core of the protein. Furthermore, the wild 
type is more hydrophobic and positively charge allowing it 
to form a salt bridge with aspartic acid at position 98, which 
is required for proper protein folding. Replacing it with a 
neutral and less hydrophobic mutant residue will distort the 
protein folding and also affect its ability to interact with other 
molecules—an important function of the domain. The mutant 
residue for the p.Gln438Leu is smaller and less hydrophobic, 
thus, affecting the interaction with other residues within the 
domain as well as the binding capacity of the domain. Unlike 
the previous two mutations where the wild type residue is 
highly conserved at their respective positions, the wild type 
is not conserved at this amino acid position (438). However, 
the mutant residue was also not among the residue types that 
have been observed at this position. Thus, why it was pre-
dicted as damaging to the protein by Sift and Polyphen-2 
would require further study, perhaps using zebrafish or a 
cell-based assay as previously reported for other variants (Li 
et al., 2017).
When we reviewed the family data for the proband with 
the p.Phe36Tyr mutation, we observed that VWS was present 
in the mother. A family history of different types of clefts, the 
presence of lower lip pits, and types of cancer such as breast 
and colon cancer were found on the maternal side of the fam-
ily. IRF6 has shown tumor-suppressor activities in different 
cancer types (Botti et al., 2011) suggesting a possible con-
nection. Other families did not provide access to the parental 
data so we were unable to ascertain the pattern of inheritance 
or the possibility of a de novo mutation.
A recent study functionally tested some IRF6 variants in 
zebrafish embryo and did not find any correlation between the 
Polyphen-2 and SIFT prediction and functional consequences 
in zebrafish embryos (Li et  al.,  2017). However, when we 
reviewed the CADD score for the variants with functional 
consequences in zebrafish from the Li et al. (2017) study, we 
observed that over 95% of the variants had CADD scores >25 . 
This observation further buttresses the relationship between 
high CADD score and the likelihood of pathogenicity (van 
der Velde et al., 2017) . However, caution should be exercised 
so as not to use CADD score alone to assign pathogenicity 
and efforts should be made to follow the guidelines set by 
the American College of Medical Genetics and Genomics 
(ACMGG) for assigning pathogenicity to sequence vari-
ants (Richards et al., 2015). The previous work by De Lima 
et al. (2009) and Leslie et al. (2013) showed the distribution 
of mutations in IRF6 to be non-random, segregating primar-
ily in the DNA-binding (exon 3 and 4), and protein-binding 
domains (exon 7–9). Since most of these mutations were in 
exon 4, thus they proposed a major function for the DNA-
binding domain in the activities of IRF6. However, when 30 
missense mutations (16 in the DNA-binding domain and 14 in 
the protein-binding domain) of IRF6 were isolated in patients 
with VWS and PPS were functionally tested in zebrafish em-
bryos, 50% (15) were shown to be pathogenic. Most (11) of 
the pathogenic variants in zebrafish were in the protein-bind-
ing domain (exons 7–9). Furthermore, we observed a higher 
rate of nonsense mutations with very high CADD scores in 
the protein-coding domain which are pathogenic. Finally, we 
also observed that the mutation that resulted in G/C in the 
DNA-binding domain and A/T in the protein-binding domain 
tends to be more common among the variants that induced 
rupture (pathogenic) in the Li et al. (2017) study.
5 |  CONCLUSION
In conclusion, findings from the current study provided addi-
tional information on VWS mutations which is important for 
diagnostic and counseling purposes especially for families 
with a previous history.
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